A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma
Bispecific T-cell engagers (BTCEs) represent a paradigm shift in the treatment of relapsed/refractory multiple myeloma (RRMM). Talquetamab, a GPRC5DxCD3 BTCE, has shown promising results in the MonumenTAL-1 trial and was recently approved by the Food and Drug Administration and the European Medicine...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
April 2025
|
| In: |
HemaSphere
Year: 2025, Jahrgang: 9, Heft: 4, Pages: 1-16 |
| ISSN: | 2572-9241 |
| DOI: | 10.1002/hem3.70114 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1002/hem3.70114 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/hem3.70114 
|
| Verfasserangaben: | Jan H. Frenking, Christine Riedhammer, Raphael Teipel, Florian Bassermann, Britta Besemer, Moritz Bewarder, Jan Braune, Annamaria Brioli, Franziska Brunner, Maria Dampmann, Roland Fenk, Deniz N. Gezer, Sarah Goldman-Mazur, Christine Hanoun, Marion Högner, Cyrus Khandanpour, Katja Kolditz, Igor Kos, Jan Krönke, Miriam Kull, Valentine Landrin, Theo Leitner, Maximilian Merz, Ivana von Metzler, Christian S. Michel, Carsten Müller-Tidow, Sebastian Theurich, Karolin Trautmann-Grill, Ralph Wäsch, Romans Zukovs, Mathias Hänel, Leo Rasche, Marc S. Raab |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1938333144 | ||
| 003 | DE-627 | ||
| 005 | 20251204122840.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251014s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hem3.70114 |2 doi | |
| 035 | |a (DE-627)1938333144 | ||
| 035 | |a (DE-599)KXP1938333144 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Frenking, Jan |e VerfasserIn |0 (DE-588)1181399858 |0 (DE-627)1662669607 |4 aut | |
| 245 | 1 | 2 | |a A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma |c Jan H. Frenking, Christine Riedhammer, Raphael Teipel, Florian Bassermann, Britta Besemer, Moritz Bewarder, Jan Braune, Annamaria Brioli, Franziska Brunner, Maria Dampmann, Roland Fenk, Deniz N. Gezer, Sarah Goldman-Mazur, Christine Hanoun, Marion Högner, Cyrus Khandanpour, Katja Kolditz, Igor Kos, Jan Krönke, Miriam Kull, Valentine Landrin, Theo Leitner, Maximilian Merz, Ivana von Metzler, Christian S. Michel, Carsten Müller-Tidow, Sebastian Theurich, Karolin Trautmann-Grill, Ralph Wäsch, Romans Zukovs, Mathias Hänel, Leo Rasche, Marc S. Raab |
| 246 | 3 | 0 | |a onehundredthirtyeight |
| 264 | 1 | |c April 2025 | |
| 300 | |b Illustrationen | ||
| 300 | |a 16 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Zuerst veröffentlicht: 17. April 2025 | ||
| 500 | |a Gesehen am 14.10.2025 | ||
| 520 | |a Bispecific T-cell engagers (BTCEs) represent a paradigm shift in the treatment of relapsed/refractory multiple myeloma (RRMM). Talquetamab, a GPRC5DxCD3 BTCE, has shown promising results in the MonumenTAL-1 trial and was recently approved by the Food and Drug Administration and the European Medicines Agency. However, treatment under real-world conditions may not represent patient characteristics in clinical trials with restricted enrollment criteria. We performed a retrospective real-world analysis including 138 RRMM patients treated with talquetamab at 21 German centers. Of evaluable patients, 43% had ISS stage III, 37% had extraosseous disease, and 48% had high-risk cytogenetics. After a median of six prior therapy lines, 58% of patients would not have been eligible for MonumenTAL-1. With a median follow-up of 8.2 months, we observed an overall response rate of 65% and a median progression-free survival of 6.4 months (95% confidence interval 5.1-9.0). Prior BTCE exposure, ISS stage III, extraosseous disease, and penta-drug refractory disease were associated with unfavorable outcomes. Grade ≥ 3 cytokine release syndrome and neurotoxicity occurred in 5.1% and 1.5% of patients, respectively. In summary, our real-world study confirms the efficacy and safety of talquetamab, despite a high proportion of patient- and disease-related risk factors. These results support its use as bridging or long-term treatment, even in advanced stages. | ||
| 700 | 1 | |a Riedhammer, Christine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Teipel, Raphael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bassermann, Florian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Besemer, Britta |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bewarder, Moritz |e VerfasserIn |4 aut | |
| 700 | 1 | |a Braune, Jan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brioli, Annamaria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brunner, Franziska |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dampmann, Maria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fenk, Roland |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gezer, Deniz N. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldman-Mazur, Sarah |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hanoun, Christine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Högner, Marion |e VerfasserIn |4 aut | |
| 700 | 1 | |a Khandanpour, Cyrus |d 1977- |e VerfasserIn |0 (DE-588)130838004 |0 (DE-627)506356671 |0 (DE-576)298368315 |4 aut | |
| 700 | 1 | |a Kolditz, Katja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kos, Igor |e VerfasserIn |4 aut | |
| 700 | 1 | |a Krönke, Jan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kull, Miriam |e VerfasserIn |4 aut | |
| 700 | 1 | |a Landrin, Valentine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Leitner, Theo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Merz, Maximilian |e VerfasserIn |4 aut | |
| 700 | 1 | |a von Metzler, Ivana |e VerfasserIn |4 aut | |
| 700 | 1 | |a Michel, Christian S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Müller-Tidow, Carsten |d 1968- |e VerfasserIn |0 (DE-588)1015101798 |0 (DE-627)705330230 |0 (DE-576)351197893 |4 aut | |
| 700 | 1 | |a Theurich, Sebastian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Trautmann-Grill, Karolin |e VerfasserIn |4 aut | |
| 700 | 1 | |8 1\p |a Wäsch, Ralph |d 1965- |e VerfasserIn |0 (DE-588)118204807 |0 (DE-627)079304893 |0 (DE-576)291768458 |4 aut | |
| 700 | 1 | |a Zukovs, Romans |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hänel, Mathias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rasche, Leo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Raab, Marc-Steffen |d 1973- |e VerfasserIn |0 (DE-588)124052460 |0 (DE-627)706520998 |0 (DE-576)293998027 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t HemaSphere |d Hoboken : John Wiley & Sons Ltd., 2017 |g 9(2025), 4 vom: Apr., Artikel-ID e70114, Seite 1-16 |h Online-Ressource |w (DE-627)1015324924 |w (DE-600)2922183-3 |w (DE-576)500571066 |x 2572-9241 |7 nnas |a A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma |
| 773 | 1 | 8 | |g volume:9 |g year:2025 |g number:4 |g month:04 |g elocationid:e70114 |g pages:1-16 |g extent:16 |a A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma |
| 856 | 4 | 0 | |u https://doi.org/10.1002/hem3.70114 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/hem3.70114 |x Verlag |z kostenfrei |3 Volltext |
| 883 | |8 1\p |a cgwrk |d 20251101 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 951 | |a AR | ||
| 992 | |a 20251014 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 124052460 |a Raab, Marc-Steffen |m 124052460:Raab, Marc-Steffen |d 910000 |d 910100 |e 910000PR124052460 |e 910100PR124052460 |k 0/910000/ |k 1/910000/910100/ |p 33 |y j | ||
| 998 | |g 1015101798 |a Müller-Tidow, Carsten |m 1015101798:Müller-Tidow, Carsten |d 910000 |d 910100 |e 910000PM1015101798 |e 910100PM1015101798 |k 0/910000/ |k 1/910000/910100/ |p 26 | ||
| 998 | |g 1181399858 |a Frenking, Jan |m 1181399858:Frenking, Jan |d 910000 |d 910100 |e 910000PF1181399858 |e 910100PF1181399858 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1938333144 |e 4786847763 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"noteIll":"Illustrationen","extent":"16 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"doi":["10.1002/hem3.70114"],"eki":["1938333144"]},"relHost":[{"pubHistory":["Volume 1, issue 1 (December 2017)-"],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"1015324924","disp":"A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myelomaHemaSphere","language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["2572-9241"],"zdb":["2922183-3"],"eki":["1015324924"]},"part":{"pages":"1-16","year":"2025","volume":"9","text":"9(2025), 4 vom: Apr., Artikel-ID e70114, Seite 1-16","issue":"4","extent":"16"},"note":["Gesehen am 18.01.2024"],"origin":[{"dateIssuedKey":"2024","publisherPlace":"Hoboken ; [Philadelphia, Pennsylvania]","publisher":"John Wiley & Sons Ltd. ; Wolters Kluwer Health","dateIssuedDisp":"2024-"}],"corporate":[{"display":"European Hematology Association","role":"isb"}],"title":[{"title":"HemaSphere","subtitle":"open access journal of the European Hematology Association","title_sort":"HemaSphere"}]}],"note":["Zuerst veröffentlicht: 17. April 2025","Gesehen am 14.10.2025"],"person":[{"role":"aut","family":"Frenking","given":"Jan","display":"Frenking, Jan"},{"role":"aut","family":"Riedhammer","given":"Christine","display":"Riedhammer, Christine"},{"role":"aut","family":"Teipel","given":"Raphael","display":"Teipel, Raphael"},{"role":"aut","display":"Bassermann, Florian","given":"Florian","family":"Bassermann"},{"given":"Britta","display":"Besemer, Britta","family":"Besemer","role":"aut"},{"role":"aut","family":"Bewarder","display":"Bewarder, Moritz","given":"Moritz"},{"family":"Braune","given":"Jan","display":"Braune, Jan","role":"aut"},{"role":"aut","display":"Brioli, Annamaria","given":"Annamaria","family":"Brioli"},{"family":"Brunner","display":"Brunner, Franziska","given":"Franziska","role":"aut"},{"role":"aut","family":"Dampmann","display":"Dampmann, Maria","given":"Maria"},{"family":"Fenk","display":"Fenk, Roland","given":"Roland","role":"aut"},{"role":"aut","display":"Gezer, Deniz N.","given":"Deniz N.","family":"Gezer"},{"given":"Sarah","display":"Goldman-Mazur, Sarah","family":"Goldman-Mazur","role":"aut"},{"family":"Hanoun","given":"Christine","display":"Hanoun, Christine","role":"aut"},{"given":"Marion","display":"Högner, Marion","family":"Högner","role":"aut"},{"display":"Khandanpour, Cyrus","given":"Cyrus","family":"Khandanpour","role":"aut"},{"role":"aut","display":"Kolditz, Katja","given":"Katja","family":"Kolditz"},{"role":"aut","family":"Kos","given":"Igor","display":"Kos, Igor"},{"given":"Jan","display":"Krönke, Jan","family":"Krönke","role":"aut"},{"given":"Miriam","display":"Kull, Miriam","family":"Kull","role":"aut"},{"role":"aut","family":"Landrin","display":"Landrin, Valentine","given":"Valentine"},{"role":"aut","display":"Leitner, Theo","given":"Theo","family":"Leitner"},{"role":"aut","family":"Merz","given":"Maximilian","display":"Merz, Maximilian"},{"given":"Ivana","display":"von Metzler, Ivana","family":"von Metzler","role":"aut"},{"role":"aut","family":"Michel","given":"Christian S.","display":"Michel, Christian S."},{"role":"aut","family":"Müller-Tidow","given":"Carsten","display":"Müller-Tidow, Carsten"},{"display":"Theurich, Sebastian","given":"Sebastian","family":"Theurich","role":"aut"},{"family":"Trautmann-Grill","display":"Trautmann-Grill, Karolin","given":"Karolin","role":"aut"},{"family":"Wäsch","given":"Ralph","display":"Wäsch, Ralph","role":"aut"},{"family":"Zukovs","display":"Zukovs, Romans","given":"Romans","role":"aut"},{"role":"aut","display":"Hänel, Mathias","given":"Mathias","family":"Hänel"},{"role":"aut","family":"Rasche","display":"Rasche, Leo","given":"Leo"},{"given":"Marc-Steffen","display":"Raab, Marc-Steffen","family":"Raab","role":"aut"}],"recId":"1938333144","name":{"displayForm":["Jan H. Frenking, Christine Riedhammer, Raphael Teipel, Florian Bassermann, Britta Besemer, Moritz Bewarder, Jan Braune, Annamaria Brioli, Franziska Brunner, Maria Dampmann, Roland Fenk, Deniz N. Gezer, Sarah Goldman-Mazur, Christine Hanoun, Marion Högner, Cyrus Khandanpour, Katja Kolditz, Igor Kos, Jan Krönke, Miriam Kull, Valentine Landrin, Theo Leitner, Maximilian Merz, Ivana von Metzler, Christian S. Michel, Carsten Müller-Tidow, Sebastian Theurich, Karolin Trautmann-Grill, Ralph Wäsch, Romans Zukovs, Mathias Hänel, Leo Rasche, Marc S. Raab"]},"origin":[{"dateIssuedDisp":"April 2025","dateIssuedKey":"2025"}],"language":["eng"],"title":[{"title":"A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma","title_sort":"German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma"}]} | ||
| SRT | |a FRENKINGJAGERMANMULT2025 | ||